Carbapenem resistance in a clinical isolate of Citrobacter freundii
- 1 November 1997
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 41 (11) , 2352-2354
- https://doi.org/10.1128/aac.41.11.2352
Abstract
Carbapenem resistance was studied in two sets of Citrobacter freundii strains: (i) strain CFr950, resistant to imipenem (MIC, 16 microg/ml) and isolated in vivo during imipenem therapy, and strain CFr950-Rev, the spontaneous, imipenem-susceptible revertant of CFr950 selected in vitro, and (ii) strains CFr801 and CFr802, two imipenem-resistant mutants selected in vitro from the susceptible clinical isolate CFr800. In all strains, whether they were imipenem-susceptible or -resistant strains, production of the cephalosporinase was derepressed and their Km values for cephaloridine were in the range of 128 to 199 microM. No carbapenemase activity was detected in vitro. The role of cephalosporinase overproduction in the resistance was demonstrated after introduction of the ampD gene which decreased the level of production of cephalosporinase at least 250-fold and resulted in an 8- to 64-fold decrease in the MICs of the carbapenems. The role of reduced permeability in the resistance was suggested by the absence, in CFr950 and CFr802, of two outer membrane proteins (the 42- and 40-kDa putative porins whose levels were considerably decreased in CFr801) and the reappearance of the 42-kDa protein in imipenem-susceptible strain CFr950-Rev. This role was confirmed after introduction of the ompF gene of Escherichia coli into the CFr strains, which resulted in 8- to 16-fold decreases in the MICs of carbapenems for CFr802 and CFr950. We infer from these results that the association of reduced, porin-mediated permeability with high-level cephalosporinase production, observed previously in other gram-negative bacteria, may also confer carbapenem resistance on C. freundii.Keywords
This publication has 24 references indexed in Scilit:
- Imipenem resistance inEnterobacterEuropean Journal of Clinical Microbiology & Infectious Diseases, 1993
- Emergence of Resistance to Imipenem in Enterobacter Isolates Masquerading as Klebsiella pneumoniae During Therapy with Imipenem/CilastatinClinical Infectious Diseases, 1993
- Activity of the β-lactamase inhibitor BRL 42715 against cephalosporinases produced by EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 1993
- Imipenem resistance in Enterobacter aerogenes is associated with derepression of chromosomal cephalosporinases and impaired permeabilityFEMS Microbiology Letters, 1992
- Imipenem resistance in Proteus mirabilisJournal of Antimicrobial Chemotherapy, 1991
- Enhanced resistance to cefotaxime and imipenem associated with outer membrane protein alterations in Enterobacter aerogenesJournal of Antimicrobial Chemotherapy, 1990
- Regulation of enterobacterial cephalosporinase production: the role of a membrane‐bound sensory transducerMolecular Microbiology, 1989
- Tigemonam activity against clinical isolates of Enterobacteriaceae and Enterobacteriaceae with known mechanisms of resistance to β-lactam antibioticsJournal of Antimicrobial Chemotherapy, 1989
- Cross-Resistance to Nalidixic Acid, Trimethoprim, and Chloramphenicol Associated with Alterations in Outer Membrane Proteins of Klebsiella, Enterobacter, and SerratiaThe Journal of Infectious Diseases, 1985
- The Use of Analytical Isoelectric Focusing for Detection and Identification of -LactamasesJournal of General Microbiology, 1975